CMP* (Rs) 289 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105

Similar documents
Sonata Software HOLD. Unimpressive Show; IITS Revenue Disappoints. Institutional Equity Research. February 06, Target Price Rs190.

CMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5

BUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017

CMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62

CMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6

CMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133

CMP* (Rs) 203 Upside/ (Downside) (%) 23. Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572

CMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417

CMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245

Nestlé India Outlook Hazy; Valuations Prohibitive

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452

HOLD. Nestle. Good Performance Irrespective of GST Pangs. Target Price: Rs6,624. Institutional Equity Research. 2QCY17 Result Update July 27,2017

CMP* (Rs) 346 Upside/ (Downside) (%) 17. Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399

CMP* (Rs) 161 Upside/ (Downside) (%) 19 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 172 Upside/ (Downside) (%) 11.6 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143

Titan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.

BUY NCC. An Ordinary Quarterly Performance; Maintain BUY. Target Price: Rs98. Institutional Equity Research. 4QFY17 Result Update May 24, 2017

HOLD ACC. Strong Performance on Better Volume and Firm Realizations. Target Price: Rs1,640. Institutional Equity Research

CMP (Rs) 326 Upside/ (Downside) (%) 24. Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67

BUY NTPC. Higher Regulated Equity to Aid Profitability; Maintain BUY. Target Price: Rs192. Institutional Equity Research

CMP (Rs) 249 Upside/ (Downside) (%) Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3

CMP* (Rs) 237 Upside/ (Downside) (%) 29 Bloomberg Ticker. APTY IN Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509

BUY. DCB Bank. Improving Capital Consumption to Aid Returns; Maintain BUY. Target Price: Rs202. Institutional Equity Research

KNR Constructions Robust Performance on Execution Ramp-up

CMP* (Rs) 198 Upside/ (Downside) (%) 12. Market Cap. (Rs bn) 61 Free Float (%) 84 Shares O/S (mn) 308

CMP* (Rs) 145 Upside/ (Downside) (%) 32 Bloomberg Ticker BOB IN Market Cap. (Rs bn) 384 Free Float (%) 36 Shares O/S (mn) 2,646

CMP* (Rs) 189 Upside/ (Downside) (%) (1) Bloomberg Ticker PNB IN Market Cap. (Rs bn) 402 Free Float (%) 38 Shares O/S (mn) 2,128

Sonata Software BUY. Laying the Platform for Growth. Institutional Equity Research. December 01, Target Price Rs185.

CMP (Rs) 133 Upside/ (Downside) (%) 35 Bloomberg Ticker. ICEM IN Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1

CMP* (Rs) 1,424 Upside/ (Downside) (%) 19 Bloomberg Ticker Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188

CMP (Rs) 702 Upside/ (Downside) (%) 42 Bloomberg Ticker. JKCE IN Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3

CMP (Rs) 166 Upside/ (Downside) (%) (1) Bloomberg Ticker Market Cap. (Rs bn) 125 Free Float (%) 37 Shares O/S (mn) 726

Near-term pressure, but long-term outlook positive

Sonata Software. On growth path BUY RESULTS REVIEW 1QFY18 16 AUG Highlights of the quarter

Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017

Jubilant FoodWorks. Institutional Equity Research. Sector - FMCG. RSec TradEdge India. January 17, 2017

Cyient. Good show, priced in NEUTRAL RESULTS REVIEW 4QFY17 21 APRIL Highlights of the quarter

BLS International Services

Hexaware Technologies

Crompton Greaves Consumer Electricals

Sonata Software. Strong growth, reasonable valuations. Source: Company Data; PL Research

Healty cigarette-driven growth

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Multi Commodity Exchange

CMP* (Rs) 301 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65

Intellect Design Arena

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Crompton Greaves Consumer Electricals

Central Depository Services

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Central Depository Services

Central Depository Services

Amber Enterprises India Ltd

Strides Arcolab. Inline 4Q, recent acquisitions to deepen asset growth. Institutional Equity Research. Strides Arcolab. Pharmaceuticals India

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Visaka Industries Ltd

Ahluwalia Contracts. Cautious optimism BUY RESULTS REVIEW 4QFY17 31 MAY Highlights of the quarter

Tech Mahindra. 1QFY18 Result Update. Steps in the right direction, compelling valuation. Sector: Technology CMP: ` 385. Recommendation: Buy

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

KEC International. Recovering from a weak phase. Institutional Equity Research. Order inflow traction remains intact

NIIT Technologies. 2QFY19 Result Update. Robust revenue visibility, Outlook robust

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

Tata Consultancy Services (TCS)

Simplex Infrastructures

NIIT Technologies. 3QFY19 Result Update. Robust revenue visibility, Outlook robust

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

J. Kumar Infraprojects

NIIT Technologies. NEUTRAL Higher capex weighing on FCF RESULTS REVIEW 2QFY15 16 OCT 2014

KPIT. 1QFY18 Result Update. Profitability does it again, looking for sustenance. Sector: Technology CMP: ` 130. Recommendation: Hold

Adani Ports & SEZ Rating: Target price: EPS:

Fineotex Chemical Ltd

Mphasis. 1QFY18 Result Update. Margins dip; valuations not supportive. Sector: Technology CMP: ` 614. Recommendation: Sell

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Wipro. 4QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 287. Recommendation: Hold

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

HCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760

Cummins India Ltd Bloomberg Code: KKC IN

Tech Mahindra. Source: Company Data; PL Research

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

Colgate-Palmolive (India)

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

Institutional Equities

Dr Reddy s Laboratories

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

Bloomberg Code: ATA IN

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Quick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.

Timken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Hindustan Media Ventures

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Transcription:

3QFY18 Result Update February 08, 2018 CMP* (Rs) 289 Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105 IITS Revenue Continues to Remain Buoyant; Margin Growth Heartening In-line with our estimate, s USD revenue from IITS business rose by a decent 2.7% QoQ in 3QFY18 to US$37.4mn. Staging a comeback to normal level, DPS revenue surged by 165.5% QoQ to Rs5.3bn (on a lower sequential base), as the segmental revenue was impacted in 2QFY18 due to a change in go-to-market strategy of some key principals. Consolidated revenue surged by ~80% QoQ, while consolidated EBITDA margin declined by 434bps QoQ owing to a higher contribution of DPS business to revenue. However, IITS margin grew by a strong 317bps QoQ led by a higher proportion of IP revenue and lower sta cost owing to a reduction in employee base led by completion of a temporary project. Consolidated EBIT margin declined by 399bps QoQ, while adjusted net profit rose by 9.2% QoQ to Rs493mn. Share price (%) 1 mth 3 mth 12 mth Absolute performance 2.0 52.6 51.3 Relative to Nifty 2.6 50.0 30.8 Shareholding Pattern (%) Sep'17 Dec'17 Promoter 31.0 31.0 Public 69.1 69.1 From vertical perspective, following two successive quarters of growth, OPD revenue declined by 0.8%. On a positive note, Sonata won some new clients towards 3QFY18-end, ramp-ups for which should start reflecting by 1QFY19E. Aided by Sonata s focus on platforms, Travel and CPG & Retail verticals clocked strong revenue growth of 6.6% and 6.7% QoQ, respectively. Service-wise, Testing and Microsoft AX were the key growth drivers, which grew by 8.5% QoQ and 8.2% QoQ, respectively. Notably, AX being the 2nd largest service after ADM (with 20% revenue contribution), higher revenue reflects Sonata s strong relationship with Microsoft. Geowise, growth was evenly spread across geographies, with the US, Europe and Rest of the World clocking 2.7% QoQ growth each. IP Revenue Drives Growth & Margin Following two successive quarters of strong growth, Sonata delivered another good quarter in IITS revenue, which rose by 2.7% QoQ in USD terms. This growth comes on top of 11.3% QoQ and 6.5% QoQ growth in 2QFY18 and 1QFY18, respectively. On YoY basis, IITS revenue (in USD terms) rose by a strong 23.4% marking the fastest growth since 2QFY15 led by focus on platforms and IP-led solutions (platformation). Focus on consumer-centric verticals which require high investment in digital initiatives continues to remain the key tailwind. Notably, 15.2% of Sonata s 3QFY18 revenue was IP-led (vs. 15% in 2QFY18 and 14% in 1QFY18). We expect focus on its platformation strategy to drive growth and profitability, going forward. 1 Year Stock Price Performance 320 280 240 200 160 120 Feb-17 Mar-17 Apr-17 May-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Note: * CMP as on Feb. 08, 2018 Nov-17 Dec-17 Jan-18 Feb-18 Outlook & Valuation We like Sonata s dierentiated business, high dividend yield, quality balance sheet, high RoE and lack of equity dilution in last 17 years. Notwithstanding sharp run-up in stock price in last couple of months, we envisage enough legroom for further upside on the back of Sonata s platform focus, investments made in IP and S&M, decent cash generation and reasonable valuation coupled with healthy growth (18.3% EPS CAGR over FY17-FY20E). We raise our EPS estimates 4-6% for FY18E and FY19E. Upgrading our PE multiple to 14x from 12x on higher growth, we maintain our recommendation on the stock with a revised Target Price of Rs340 (from Rs234 earlier). Key Financials (Rs mn) FY17 FY18E FY19E FY20E Net Sales 25,211 26,586 29,948 33,495 EBITDA 1,923 2,272 2,773 3,421 APAT 1,537 1,880 2,134 2,546 Diluted EPS (Rs) 14.6 17.9 20.3 24.2 P/E (x) 19.8 16.2 14.2 11.9 Research Analyst: Harit Shah Contact: 022 33201276 Email: harit.shah@relianceada.com EV / EBITDA (x) 14.5 12.1 9.7 7.6 RoE (%) 31.2 34.0 33.7 34.4 1

Conference Call Key Highlights Headcount in IITS business declined by ~5% QoQ owing to completion of a critical project of a strategic client, as these employees were temp hires. Staging a comeback to normal levels, DPS revenue surged substantially albeit on a lower sequential base, as revenue was impacted in 2QFY18 due to a change in go-tomarket strategy of some key principals. The Management expects the OPD business to start showing growth, as it has won new clients in this business towards 3QFY18-end, which should start ramping up from 1QFY19E onward. Sonata earned ~$2.4mn revenue (+3% QoQ) from IBIS, while it earned 14-15% EBITDA margin (vs. 11% in 2QFY18 and just 5% in 1QFY18), reflecting improving performance. The Management expects a marginal benefit of the US Tax Code. Key Risks Client-specific issues in any of the Top-10 clients could impact revenue growth. Growth pangs in OPD vertical, given the disruptive impact of SMAC, could aect revenue growth. Cost escalation could impact project delivery and margins. Cannibalisation of existing revenue particularly on ADM and ERP side following strategic shift to Cloud architecture. Currency risk. Exhibit 1: Quarterly Performance (Consolidated) Particulars (Rs mn) 3QFY18 2QFY18 QoQ (%) 3QFY17 YoY (%) IITS Net Revenue (US$ mn) 37.4 36.4 2.7 30.3 23.4 Consolidated Net Revenue 7,667 4,269 79.6 5,751 33.3 Inventory Costs 5,171 1,873 176.0 3,512 47.2 Employee Costs 1,312 1,321 (0.7) 1,157 13.4 Other Operating Expenses 535 527 1.3 534 0.1 EBITDA 651 547 18.9 548 18.7 Depreciation 31 32 (3.1) 27 16.2 EBIT 619 515 20.3 521 18.9 Interest Cost 9 12 (26.4) 24 (62.8) Other Income 65 112 (41.9) 102 (36.1) PBT 675 615 9.9 599 12.8 Tax 182 163 11.7 194 (6.3) Minority Interest 0 0 1 APAT 493 451 9.2 403 22.3 E/o (adj for tax) - 2 - RPAT 493 453 8.8 403 22.3 2

Exhibit 2: Margin Break Up Particulars 3QFY18 2QFY18 QoQ (bps) 3QFY17 YoY (bps) Inventory Cost % Net Revenue 67.4 43.9 2,355 61.1 636 Employee Cost % Net Revenue 17.1 30.9 (1,383) 20.1 (301) SG&A and Other Exp. % Net Revenues 7.0 12.4 (538) 9.3 (231) EBITDA Margin (%) 8.5 12.8 (434) 9.5 (104) EBIT Margin (%) 8.1 12.1 (399) 9.1 (98) Tax Rate (%) 27.0 26.5 44 32.5 (550) APAT Margin (%) 6.4 10.6 (414) 7.0 (58) Exhibit 3: Key Assumptions Particulars FY17 FY18E FY19E FY20E IITS USD revenue growth (%) 12.6 20.0 17.5 15.0 USD/INR rate 67.17 65.00 65.00 65.00 IITS EBITDA margin (%) 17.7 18.0 18.5 19.0 DPS EBITDA margin (%) 2.9 3.5 4.0 5.0 Cons. EBITDA margin (%) 7.6 8.5 9.3 10.2 Exhibit 4: Vertical break-up OPD 30.0 31.0 30.0 29.0 30.0 29.0 28.0 TTL 29.0 28.0 26.0 27.0 28.0 27.0 28.0 CPG & Retail 24.0 23.0 27.0 26.0 24.0 26.0 27.0 Others 17.0 18.0 17.0 18.0 18.0 18.0 17.0 Exhibit 5: Vertical growth OPD 9.8 10.4 (6.0) (2.1) 10.2 7.6 (0.8) TTL (4.2) 3.2 (9.8) 5.2 10.5 7.3 6.6 CPG & Retail 2.5 2.4 14.0 (2.4) (1.7) 20.6 6.7 Others 2.5 13.1 (8.3) 7.3 6.5 11.3 (3.0) 3

Exhibit 6: Service line break-up ADM 25.0 26.0 24.0 25.0 23.0 23.0 23.0 Testing 15.0 16.0 17.0 17.0 19.0 18.0 19.0 AX 16.0 15.0 15.0 15.0 17.0 19.0 20.0 ERP 4.0 4.0 5.0 5.0 5.0 5.0 4.0 IMS 16.0 18.0 19.0 19.0 18.0 17.0 17.0 BI 9.0 9.0 9.0 8.0 8.0 7.0 8.0 E-commerce 7.0 6.0 6.0 6.0 5.0 6.0 5.0 Mobility* 2.0 1.0 2.0 1.0 1.0 5.0 4.0 Cloud 1.0 1.0 Rezopia 5.0 4.0 3.0 4.0 4.0 ; Mobility and Cloud have been clubbed together wef. 3QFY17, and Rezopia has also been included as part of Mobility wef. 2QFY18. Exhibit 7: Service line growth ADM 11.4 11.1 (10.4) 5.5 (2.0) 11.3 2.7 Testing (14.6) 14.0 3.2 1.3 19.0 5.5 8.5 AX 9.3 0.2 (2.9) 1.3 20.7 24.4 8.2 ERP 2.5 6.8 21.4 1.3 6.5 11.3 (17.8) IMS 9.3 20.2 2.5 1.3 0.9 5.1 2.7 BI 2.5 6.8 (2.9) (9.9) 6.5 (2.6) 17.4 E-commerce (20.3) (8.4) (2.9) 1.3 (11.2) 33.6 (14.4) Mobility* 2.5 (46.6) (2.9) (49.3) 6.5 11.3 (17.8) Cloud (48.8) 6.8 Rezopia 70.8 (14.5) (27.2) 35.1 6.5 ; Mobility and Cloud have been clubbed together wef. 3QFY17, and Rezopia has also been included as part of Mobility wef. 2QFY18. Exhibit 8: Geographic break-up USA 61.0 59.0 60.0 60.0 60.0 59.0 59.0 Europe 26.0 26.0 24.0 24.0 26.0 27.0 27.0 RoW 13.0 15.0 16.0 16.0 14.0 14.0 14.0 Exhibit 9: Geographic growth USA 4.2 3.3 (1.2) 1.3 6.5 9.5 2.7 Europe 2.5 6.8 (10.4) 1.3 15.4 15.6 2.7 RoW (4.9) 23.3 3.6 1.3 (6.8) 11.3 2.7 4

Exhibit 10: Onsite-oshore contribution Onsite 42.0 45.0 40.0 43.0 43.0 45.0 45.0 Oshore 58.0 55.0 60.0 57.0 57.0 55.0 55.0 Exhibit 11: Onsite-oshore growth Onsite 0.1 14.5 (13.7) 8.9 6.5 16.5 2.7 Oshore 4.3 1.3 5.9 (3.7) 6.5 7.4 2.7 Exhibit 12: Client contribution Top-5 58.0 60.0 59.0 59.0 61.0 60.0 62.0 Clients 6-10 12.0 11.0 11.0 11.0 9.0 9.0 9.0 Top-10 70.0 71.0 70.0 70.0 70.0 69.0 71.0 Clients 11-20 6.0 7.0 10.0 11.0 9.0 9.0 8.0 Top-20 76.0 78.0 80.0 81.0 79.0 78.0 79.0 Non top-20 24.0 22.0 20.0 19.0 21.0 22.0 21.0 ; From 4QFY16, Sonata started giving out top-5 and top-20 client data. Exhibit 13: Client growth Top-5 2.5 10.5 (4.5) 1.3 10.1 9.5 6.2 Clients 6-10 36.6 (2.1) (2.9) 1.3 (12.9) 11.3 2.7 Top-10 7.0 8.4 (4.3) 1.3 6.5 9.7 5.7 Clients 11-20 (52.7) 24.7 38.7 11.5 (12.9) 11.3 (8.7) Top-20 (2.7) 9.7 (0.4) 2.6 3.9 9.9 4.1 Non top-20 22.9 (2.1) (11.7) (3.7) 17.7 16.6 (1.9) ; From 4QFY16, Sonata started giving out top-5 and top-20 client data. 5

Profit and Loss Statement Y/E March (Rs mn) FY17 FY18E FY19E FY20E Net Sales 25,211 26,586 29,948 33,495 Growth (%) 29.9 5.5 12.6 11.8 Total Operating Expenses 23,289 24,313 27,175 30,074 EBITDA 1,923 2,272 2,773 3,421 EBITDA (%) 7.6 8.5 9.3 10.2 EBITDA Growth (%) 0.2 18.2 22.1 23.4 Depreciation 93 130 149 167 EBIT 1,830 2,142 2,625 3,254 EBIT (%) 7.3 8.1 8.8 9.7 EBIT Growth (%) (1.5) 17.1 22.6 24.0 Other Income 403 631 554 580 Interest 91 49 41 34 PBT 2,142 2,724 3,138 3,800 Tax (incl deferred) 682 844 1,004 1,254 Minority Interest 0 0 0 0 Exceptional Items 77 0 0 0 PAT 1,537 1,880 2,134 2,546 PAT Growth (%) (3.1) 22.3 13.5 19.3 EPS (Rs) 14.6 17.9 20.3 24.2 EPS Growth (%) (3.1) 22.3 13.5 19.3 Balance Sheet Y/E March (Rs mn) FY17 FY18E FY19E FY20E SOURCES OF FUNDS Share Capital - Equity 105 105 105 105 Reserves 5,045 5,788 6,660 7,944 Total Shareholders' Funds 5,150 5,894 6,765 8,049 Total Debt 343 311 278 245 Long Term Provisions & Others 187 187 187 187 Creditors 4,482 4,796 5,584 6,344 Other Current Liabilities & Provns 1,791 1,837 1,965 2,094 Total Current Liabilities 6,274 6,633 7,549 8,439 TOTAL SOURCES OF FUNDS 11,953 13,024 14,779 16,920 APPLICATION OF FUNDS Goodwill & Other Intangible Assets 909 909 909 909 Net Block 270 406 557 725 CWIP 16 16 16 16 Deferred Tax Assets 127 127 127 127 LT Loans & Advances, Others 801 801 801 801 Total Non Current Assets 2,124 2,260 2,411 2,579 Debtors 5,443 5,973 6,974 8,075 Cash & Bank 2,477 2,883 3,486 4,358 Liquid Investments 1,178 1,178 1,178 1,178 Other Current Assets 730 730 730 730 Total Current Assets 9,829 10,764 12,368 14,342 TOTAL APPLICATION OF FUNDS 11,953 13,024 14,779 16,920 6

Cash Flow Statement Y/E March (Rs mn) FY17 FY18E FY19E FY20E PAT 1,537 1,880 2,134 2,546 Depreciation 93 130 149 167 Working Capital Change 1,120 (170) (86) (211) Cash Flow from Operations (a) 2,751 1,840 2,196 2,501 Capex (113) (266) (299) (335) Investments (0) 0 0 0 Cash Flow from Investing (b) (113) (266) (299) (335) Debt Issuance/(Repaid) (1,370) (33) (33) (33) Dividend (694) (1,136) (1,262) (1,262) Cash Flow from Financing (c) (2,064) (1,168) (1,294) (1,294) NET CASH FLOW (a+b+c) 573 406 603 872 EO items, others (1,049) 0 0 0 Closing Cash Balance 2,477 2,883 3,486 4,358 Free Cash Flow 2,637 1,574 1,897 2,166 Key Ratios Y/E March (Rs mn) FY17 FY18E FY19E FY20E Profitability (%) EBITDA Margin 7.6 8.5 9.3 10.2 APAT Margin 6.1 7.1 7.1 7.6 RoE 31.2 34.0 33.7 34.4 RoIC or Core RoCE 14.7 15.8 16.7 17.8 RoCE 25.3 26.8 28.2 29.4 Eiciency Tax Rate (%) 31.8 31.0 32.0 33.0 Fixed Asset Turnover (x) 21.3 18.3 17.1 16.1 Inventory (days) 0 0 0 0 Debtors (days) 79 82 85 88 Payables (days) 70 72 75 77 Cash Conversion Cycle (days) 9 10 10 11 Net Debt/EBITDA (x) (1.8) (1.8) (1.7) (1.6) Net Debt/Equity (x) (0.7) (0.7) (0.7) (0.7) Interest Coverage (x) 20.2 43.7 63.7 95.6 Per Share Data (Rs) EPS 14.6 17.9 20.3 24.2 CEPS 15.5 19.1 21.7 25.8 DPS 5.5 9.0 10.0 10.0 BV 49.0 56.0 64.3 76.5 Valuation P/E 19.8 16.2 14.2 11.9 P/BV 5.9 5.2 4.5 3.8 EV/EBITDA 14.5 12.1 9.7 7.6 OCF/EV (%) 9.9 6.7 8.2 9.6 FCF/EV (%) 9.5 5.7 7.1 8.3 FCFE/mkt cap (%) 8.7 5.2 6.2 7.1 Dividend Yield (%) 1.9 3.1 3.5 3.5 7

Rating Guides Rating Expected absolute returns (%) over 12 months >10% HOLD -5% to 10% REDUCE >-5% Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India s leading retail broking houses. Reliance Capital is amongst India s leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 General Disclaimers: This Research Report (hereinafter called Report ) is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or oering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, ailiates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, ailiates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely aected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces aecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be aected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may aect the pricing of derivatives. Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/ or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India. Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/ opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL s Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.rsl, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report. The research analysts has served as an oicer, director or employee of the said issuer company(ies)?: No RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL. RSL s activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/ strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report. Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of. RSL CIN: U65990MH2005PLC154052. SEBI registration no. ( Stock Brokers: NSE - INB / INF / INE 231234833; BSE - INB / INF / INE 011234839, Depository Participants: CDSL IN-DP-257-2016 IN-DP-NSDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889. 8